Pan-European collaboration is important for many clinical trials and essential for trials that are investigating treatments for rare diseases. That was the message delivered today by the European Medical Research Councils (EMRC), the membership organisation for medical research councils across Europe based at the European Science Foundation (ESF) in Strasbourg, which is coordinating two trials in rare diseases and about to launch a review of how best to implement clinical trials that are initiated by investigators.
A new drug has shown promising pre-clinical activity against cells from several types of children’s cancers, scientists reveal at the National Cancer Research Institute Conference in Birmingham.
The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung.
One of the major issues associated with longer life expectancy in man and his best friend is an increase in the incidence of cancer. Even though they cannot talk it seems dogs might be able to tell us why and how certain cancers develop.
Logan Spector, Ph.D., a University of Minnesota Cancer Center researcher, has received a $1.7 million grant from the National Cancer Institute (NCI) to lead the largest and most comprehensive study to date on the causes of pediatric osteosarcoma.
IDM Pharma, Inc. (NASDAQ: IDMI) announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 that the results of INT 0133, the Phase 3 trial, do not provide substantial evidence of effectiveness of Junovan (mifamurtide) in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy.
Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, have determined that children and young adults with a form of cancer called sarcoma are at increased risk of having a thromboembolic event (TE) in their veins. Thromboembolic events can be a blood clot in a vessel that can interfere with normal blood flow.
Researchers at the University of Illinois have found that a molecular pathway known to have a role in the progression of bone cancer in humans is also critical to the pathology of skeletal tumors in dogs and cats.
Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma — a cancer of connective or supportive tissue such as bone, fat, or muscle — compared with the general population, according to a study in the February 21 Journal of the National Cancer Institute.
IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted a Marketing Authorization Application (MAA) in eCTD format (electronic common technical document) to the European Medicines Agency (EMEA) for Mepact (mifamurtide for injection), requesting approval for its use in the treatment of patients with newly diagnosed resectable high-grade osteosarcoma following surgical resection in combination with post-operative multi-agent chemotherapy. This announcement follows the October 25, 2006 submission of a New Drug Application (NDA) for Junovan (mifamurtide for injection) to the Food and Drug Administration (FDA) in the United States.